Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that less than one-third of primary care physicians (PCPs) and psychiatrists expect the launch of generic forms of Janssen's Risperdal (risperidone) and Pfizer's Geodon (ziprasidone) to increase the overall number of prescriptions written for antipsychotic drugs following the patent expiries of these two therapies in 2007. Antipsychotic drugs are used both on- and off- label to treat a number of diseases including schizophrenia, bipolar disorder, and dementia.

The new PhysicianForum primary market research report Antipsychotics: Current Prescription Patterns and the Impact of Patent Expiries also finds that many health maintenance organizations will no longer include branded versions of risperidone and ziprasidone in their product formularies following the launch of generic forms of these drugs.

"Although physicians do not plan to increase the number of antipsychotics prescriptions they write, 20% to 50% of PCPs and psychiatrists say they are more likely to prescribe risperidone and ziprasidone when they are available as a generic than they were prior to generic availability," said Michelle Grady, director at Decision Resources, Inc.

Antipsychotics: Current Prescription Patterns and the Impact of Patent Expiries is based on a U.S. survey of 21 HMO pharmacy and medical directors, 73 psychiatrists, and 70 primary care physicians. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.

About PhysicianForum

PhysicianForum is a primary research service from Decision Resources that offers access to high-volume-prescribing PCPs, specialists, and managed care organization representatives in the United States. PhysicianForum offers analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Young and Hungry: Smaller, Emerging Pharmaceutical Companies Developing Promising Treatments for Metabolic Diseases

View Now